source
- Electra Therapeutics raises $350M in biotech IPO, fueling rare disease drug developmentElectra Therapeutics completed a $350 million initial public offering, becoming the 21st biotechnology company to go public in 2026. The strong demand for its shares highlights continued investor a…
- GSK adds two China cancer-therapy licensing deals, keeping pace with industry partnership surgeBioPharma Dive's new visualization series recapped recent activity, spotlighting GSK's licensing agreements in China and the market response. Since the start of 2025, GSK has signed five deals wit…